Video

Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

Author(s):

Kami J. Maddocks, MD,Alexey V. Danilov, MD, PhD

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.

Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
1 expert in this video
Related Content
Mantle cell lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 18th 2024

Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL

Lori A. Leslie, MD
February 27th 2023

FDA Approval Insights: Pirtobrutinib in MCL

Myelofibrosis | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 18th 2024

Acalabrutinib Regimen Demonstrates Efficacy in De Novo Mantle Cell Lymphoma

Joshua Brody, MD
December 8th 2022

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

Mantle Cell Lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 10th 2024

Autologous HCT Does Not Provide Added Survival Benefit in Patients With MCL in First CR

Mantle Cell Lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 10th 2024

Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL